Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Source: SeekingAlpha
2026-04-27 20:16:55 ET
Recursion Pharmaceuticals, Inc. ( RXRX ) describes itself as a "clinical-stage TechBio company decoding biology to radically improve lives." The company’s vision is based on the premise that most diseases – they estimate around 80% – still lack disease-modifying therapies, and that AI can be harnessed in the drug discovery phase to expedite the process of identifying potential therapies....
Read the full article on Seeking Alpha
For further details see:
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Novartis AG
NASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
